Dr. Sulaiman Al Habib Medical Services Group (HMG)

2Q2025 First Look

Market Data	
52-week high/low	SAR 313.4/240.0
Market Cap	SAR 90,300 mln
Shares Outstanding	350 mln
Free-float	29.14%
12-month ADTV	193,835
Bloomberg Code	SULAIMAN AB



Growth Story Intact, Upgrade to Buy

August 12, 2025

Upside to Target Price	20.2%	Rating	Buy
Expected Dividend Yield	1.9%	Last Price	SAR 258.00
Expected Total Return	22.1%	12-mth target	SAR 310.00

HMG	2Q2025	2Q2024	Y/Y	1Q2025	Q/Q	RC Estimate
Sales	3,384	2,574	32%	3,158	7%	3,221
Gross Profit	1,066	878	21%	1,028	4%	1,044
Gross Margins	32%	34%		33%		32%
Operating Profit	645	552	17%	625	3%	639
Net Profit	591	555	6%	557	6%	580

(All figures are in SAR mln)

- 2Q revenues jumped +32% Y/Y and +7% Q/Q to SAR 3.38 bln, beating our SAR 3.22 bln forecast. The rise in the topline follows
 the strategic expansion being undertaken by the group as new hospitals and medical centers are coming online at regular
 intervals since last year. Hospital revenues has led with a growth of +32% Y/Y for 1H2025 versus 1H2024.
- Gross margins continue to be under pressure overall for the past few quarters as higher fixed costs from the expansions has weighed in. Gross margins compressed by over 100bps Q/Q to 31.5% in 2Q2025 likely on the back of staffing, pre-opening and ramp-up costs. Operating expenses of SAR 421 mln are marginally higher by +1% versus last quarter and our estimates.
- Net income was reported at SAR 591 mln (+6% Y/Y, +6% Q/Q), in-line with our forecast of SAR 580 mln. Net margin was mostly flat on a Q/Q basis at 17.5% but is substantially below 21.9% recorded last year, largely due to ramp-up costs of new projects as detailed above.
- The solid execution of expansion plans leads us to have a long-term positive view on the growth story. HMG has managed to commence operations at the Al Hamra Hospital Riyadh, Al Kharj Hospital and Al Muhammadiyah Hospital Jeddah in 1H2O25. Market dynamics has resulted in some pressure in the HMG stock. We believe this is a good entry point to gain exposure to the health-care growth story. Hence, we upgrade our recommendation to a Buy with a target price of SAR 310.00.

Muhammad Faisal Potrik



Disclaimer

Stock Rating

Buy	Neutral	Sell	Not Rated	
Expected Total Return	Expected Total Return	Expected Total Return less than -15%	Under Review/ Restricted	
Greater than +15%	between -15% and +15%	Expected rotal Return less than -15%	Officer Neview/ Restricted	

The expected percentage returns are indicative, stock recommendations also incorporate relevant qualitative factors For any feedback on our reports, please contact research@riyadcapital.com

Riyad Capital is a Saudi Closed Joint Stock Company with Paid up capital of SR 500 million, licensed by the Saudi Arabian Capital Market Authority NO.07070-37. Commercial Registration No: 1010239234. Head Office: Granada Business Park 2414 Al-Shohda Dist. – Unit No 69, Riyadh 13241 - 7279 Saudi Arabia. Ph: 920012299. The information in this report was compiled in good faith from various public sources believed to be reliable. Whilst all reasonable care has been taken to ensure that the facts stated in this report are accurate and that the forecasts, opinions and expectations contained herein are fair and reasonable. Riyad Capital makes no representations or warranties whatsoever as to the accuracy of the data and information provided and, in particular, Riyad Capital does not represent that the information in this report is not, and is not to be construed as an offer to sell or solicitation of an offer to buy any financial securities. Accordingly, no reliance

or warranties whatsoever as to the accuracy of the data and information provided and, in particular, Riyad Capital does not represent that the information in this report is complete or free from any error. This report is not, and is not to be construed as, an offer to sell or solicitation of an offer to buy any financial securities. Accordingly, no reliance should be placed on the accuracy, fairness or completeness of the information contained in this report. Riyad Capital accepts no liability whatsoever for any loss arising from any use of this report or its contents, and neither Riyad Capital nor any of its respective directors, officers or employees, shall be in any way responsible for the contents hereof. Riyad Capital or its employees or any of its affiliates or clients may have a financial interest in securities or other assets referred to in this report. Opinions, forecasts or projections contained in this report represent Riyad Capital's current opinions or judgment as at the date of this report only and are therefore subject to change without notice. There can be no assurance that future results or events will be consistent with any such opinions, forecasts or projections which represent only one possible outcome. Further, such opinions, forecasts or projections are subject to certain risks, uncertainties and assumptions that have not been verified and future actual results or events could differ materially. The value of, or income from, any investments referred to in this report may fluctuate and/or be affected by changes. Past performance is not necessarily an indicative of future performance. Accordingly, investors may receive back less than originally invested amount. This report provides information of a general nature and does not address the circumstances, objectives, and risk tolerance of any particular investor. Therefore, it is not intended to provide personal investment advice and loss on take into account the reader's financial situation or any specific investment objectives or particular n

